CNS Pharmaceuticals (CNSP) Competitors $8.95 +0.07 (+0.79%) Closing price 10/3/2025 03:54 PM EasternExtended Trading$8.84 -0.11 (-1.28%) As of 10/3/2025 07:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CNSP vs. PRPH, AIMD, CLRB, EDSA, NRSN, THAR, MTEX, BLRX, IBIO, and LPCNShould you be buying CNS Pharmaceuticals stock or one of its competitors? The main competitors of CNS Pharmaceuticals include ProPhase Labs (PRPH), Ainos (AIMD), Cellectar Biosciences (CLRB), Edesa Biotech (EDSA), NeuroSense Therapeutics (NRSN), Tharimmune (THAR), Mannatech (MTEX), BioLineRx (BLRX), iBio (IBIO), and Lipocine (LPCN). These companies are all part of the "pharmaceutical products" industry. CNS Pharmaceuticals vs. Its Competitors ProPhase Labs Ainos Cellectar Biosciences Edesa Biotech NeuroSense Therapeutics Tharimmune Mannatech BioLineRx iBio Lipocine ProPhase Labs (NASDAQ:PRPH) and CNS Pharmaceuticals (NASDAQ:CNSP) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, media sentiment, profitability and institutional ownership. Do analysts recommend PRPH or CNSP? CNS Pharmaceuticals has a consensus price target of $20.00, indicating a potential upside of 123.46%. Given CNS Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe CNS Pharmaceuticals is more favorable than ProPhase Labs.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ProPhase Labs 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00CNS Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33 Is PRPH or CNSP more profitable? CNS Pharmaceuticals' return on equity of -183.89% beat ProPhase Labs' return on equity.Company Net Margins Return on Equity Return on Assets ProPhase LabsN/A -262.42% -76.48% CNS Pharmaceuticals N/A -183.89%-139.37% Which has more volatility & risk, PRPH or CNSP? ProPhase Labs has a beta of -0.62, meaning that its stock price is 162% less volatile than the S&P 500. Comparatively, CNS Pharmaceuticals has a beta of 2.68, meaning that its stock price is 168% more volatile than the S&P 500. Which has preferable valuation & earnings, PRPH or CNSP? CNS Pharmaceuticals has lower revenue, but higher earnings than ProPhase Labs. ProPhase Labs is trading at a lower price-to-earnings ratio than CNS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProPhase Labs$6.77M3.43-$53.36M-$1.26-0.44CNS PharmaceuticalsN/AN/A-$14.86M-$3.75 thousand0.00 Does the media favor PRPH or CNSP? In the previous week, ProPhase Labs' average media sentiment score of 0.00 equaled CNS Pharmaceuticals'average media sentiment score. Company Overall Sentiment ProPhase Labs Neutral CNS Pharmaceuticals Neutral Do insiders & institutionals have more ownership in PRPH or CNSP? 9.5% of ProPhase Labs shares are held by institutional investors. Comparatively, 14.0% of CNS Pharmaceuticals shares are held by institutional investors. 9.6% of ProPhase Labs shares are held by company insiders. Comparatively, 0.1% of CNS Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. SummaryCNS Pharmaceuticals beats ProPhase Labs on 8 of the 12 factors compared between the two stocks. Get CNS Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CNSP and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CNSP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CNSP vs. The Competition Export to ExcelMetricCNS PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.15M$3.36B$6.14B$10.58BDividend YieldN/A2.28%5.67%4.69%P/E Ratio0.0022.1478.0526.70Price / SalesN/A458.33605.13131.81Price / CashN/A47.8637.9061.31Price / Book0.149.9312.556.55Net Income-$14.86M-$52.80M$3.31B$277.50M7 Day Performance0.56%5.22%4.28%2.41%1 Month Performance45.53%13.01%7.85%9.30%1 Year Performance-87.52%25.18%71.37%31.22% CNS Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CNSPCNS Pharmaceuticals2.2794 of 5 stars$8.95+0.8%$20.00+123.5%-87.6%$5.15MN/A0.005PRPHProPhase Labs0.5485 of 5 stars$0.44-1.8%N/A-76.7%$17.95M$6.77M-0.34130AIMDAinos1.2212 of 5 stars$3.81+0.3%N/A+30.7%$17.76M$20K-0.7640News CoverageShort Interest ↓CLRBCellectar Biosciences2.2873 of 5 stars$5.51+0.2%$375.00+6,704.6%-91.1%$17.60MN/A-0.2810EDSAEdesa Biotech2.5782 of 5 stars$2.44-0.4%$5.00+104.9%-40.0%$17.28MN/A-1.8620NRSNNeuroSense Therapeutics2.138 of 5 stars$1.25-1.6%$14.00+1,020.0%+2.5%$17.03MN/A-2.3110Negative NewsShort Interest ↑THARTharimmune2.5832 of 5 stars$2.87-1.4%$17.00+492.3%+30.5%$16.93MN/A-0.472News CoverageAnalyst UpgradeShort Interest ↓MTEXMannatech0.5114 of 5 stars$8.60+0.4%N/A+26.7%$16.33M$117.87M-4.21250Gap UpBLRXBioLineRx2.9162 of 5 stars$3.83-1.2%$26.00+579.7%-80.2%$16.29M$28.94M-0.4340IBIOiBio2.4811 of 5 stars$0.81-0.4%$5.00+518.8%-63.0%$15.88M$400K-0.46100Short Interest ↓LPCNLipocine3.151 of 5 stars$2.82-2.3%$9.00+219.7%-25.2%$15.48M$11.20M-3.2810 Related Companies and Tools Related Companies PRPH Competitors AIMD Competitors CLRB Competitors EDSA Competitors NRSN Competitors THAR Competitors MTEX Competitors BLRX Competitors IBIO Competitors LPCN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CNSP) was last updated on 10/4/2025 by MarketBeat.com Staff From Our PartnersNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredURGENT: The Market's 3 Red Flags Are FlashingThe warning signs that preceded the 2008 crash are reappearing: an irrational NASDAQ bubble, a record-high gol...StockEarnings | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredU.S. Government Sparking Crypto RallySecond Chances Don't Come Often in Crypto My "Crypto Bull Run Millionaire Blueprint" reveals everything - w...Crypto 101 Media | SponsoredMiss This IRS Strategy Now, Regret It LaterWith Donald Trump back in the White House, many believe an economic revival could be underway — but it also br...American Alternative | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CNS Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CNS Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CNSP Stock Alerts